The NCRI Lung Group launched their strategic priorities in April 2023 to address challenges faced in lung tumour research and to ultimately improve outcomes for lung cancer patients with currently unmet needs. Please see the NCRI Lung Group strategic priorities 2023-2026 for further information.
Working Group 1
Identify whether a screening strategy for Lung Cancer in Never Smokers (LCINS) in the UK is feasible, and identify potential prevention interventions for those at high risk of LCINS.
Working Group 2
Scope a potential trial in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) that will improve long term outcomes.
Working Group 3
Design and implement small cell lung cancer (SCLC) trials based on a) the molecular and immunological specificities and the plasticity of the recently described transcriptional subtypes of SCLC; and b) unique immunobiology of SCLC that factors in the transcriptional repression of Major Histocompatibility Complex-I (MHC-I) and consider trials of immune therapies that are not dependent on MHC-I presentation of neoantigens.
Working Group 4
Design and implement a definitive large cell neuroendocrine carcinoma (LCNEC) trial of etoposide/cisplatin (EP) versus gemcitabine/platinum with prospective stratification by retinoblastoma (Rb) status/LCNEC subtype with or without anti- programmed death-1 (PD-1)/ ligand 1 (PD-L1) (anti-PD-1/PD-L1) immune checkpoint blockade (ICB) to determine the optimal chemo(immuno)therapy regimen for each subtype and the relative contribution of the addition of ICB in each subtype.
Working Group 5
Design and implement a series of predictive biomarkers for Immune-Related Adverse Events (irAEs) alongside efforts to optimise the treatment of those with severe irAEs.
Mesothelioma and Thymoma Study Group
This permanent study group will begin with a priority setting workshop including all key stakeholders dedicated to defining key areas of interest and relevance to clinical and translational research in mesothelioma and thymic malignancies in the UK.